Novel Biological Tissue for Vascular Patch

Information

  • Research Project
  • 9620851
  • ApplicationId
    9620851
  • Core Project Number
    R43HL140763
  • Full Project Number
    1R43HL140763-01A1
  • Serial Number
    140763
  • FOA Number
    PA-17-302
  • Sub Project Id
  • Project Start Date
    9/1/2018 - 6 years ago
  • Project End Date
    8/31/2019 - 5 years ago
  • Program Officer Name
    LUNDBERG, MARTHA
  • Budget Start Date
    9/1/2018 - 6 years ago
  • Budget End Date
    8/31/2019 - 5 years ago
  • Fiscal Year
    2018
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    8/27/2018 - 6 years ago
Organizations

Novel Biological Tissue for Vascular Patch

ABSTRACT Arterial and venous reconstructions are frequently needed to reestablish circulation in various diseases, organ transplantations, interventional operations, trauma, etc. Autologous grafts, mostly saphenous veins, are the gold standard for vascular patches to reconstruct arteries and veins. The disadvantages of autologous venous patches, however, are obvious, including multiple surgeries, limitations on dimensions and numbers of donor sites, and donor complications. Synthetic and biological materials are used to supplement autologous patches in clinical practice but have a number of shortcomings. Synthetic patches have relatively high rate of occlusion and risk of pseudoaneurysm formation and infection which may require life-long follow up in susceptible populations. Biological materials have been used to reconstruct arteries and veins with variable outcomes which suggest the need for further refinement. In this Phase I SBIR proposal, we propose to evaluate the pulmonary visceral pleura (PVP) as a biological patch for reconstruction of arteries and veins in vascular surgery. The PVP plays an important role in lung function, and is inherently compliant and non-thrombogenic. Our preliminary data show that glutaraldehyde-fixed PVP patches implanted in carotid and femoral arteries and jugular veins maintained excellent 4-month patency and developed functional neo-endothelial and -smooth muscle cells. We hypothesize that the PVP patch will vascularize in-vivo and therefore provide long-term patency, since the non- thrombogenic nature of the structure of mesothelium and the biocompatibility of PVP patches to promote vascular tissue self-assembly. To test this hypothesis, we will validate the safety and efficacy of the PVP patches using conduit artery and vein in a translational swine model. We will carry out these studies in aged and hyperlipidemic swine model, since vascular repair or reconstruction are frequently needed in the aging patients with hyperlipidemic complications. This proposal addresses a clinically significant problem and successful completion will provide surgeons with various size options of patches for vascular surgery to ultimately improve patient outcomes. PVP is abundant (from swine, bovine, etc.) and can be fabricated into the desired sizes of vascular patches.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    419085
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:419085\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    3DT HOLDINGS, LLC
  • Organization Department
  • Organization DUNS
    804419740
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    921211206
  • Organization District
    UNITED STATES